Silence Therapeutics PLC

SLN

Company Profile

  • Business description

    Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

  • Contact

    72 Hammersmith Road
    LondonW14 8TH
    GBR

    T: +44 2034576900

    E: [email protected]

    https://www.silence-therapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    116

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,462.6040.900.49%
CAC 407,733.1138.670.50%
DAX 4023,486.09133.400.57%
Dow JONES (US)41,368.45254.480.62%
FTSE 1008,568.6036.990.43%
HKSE22,867.7491.820.40%
NASDAQ17,928.14189.981.07%
Nikkei 22537,503.33574.701.56%
NZX 50 Index12,605.07138.041.11%
S&P 5005,663.9432.660.58%
S&P/ASX 2008,231.2039.500.48%
SSE Composite Index3,342.0010.00-0.30%

Market Movers